Hanlon Investment Management Inc. Has $486,000 Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Hanlon Investment Management Inc. lifted its position in Axon Enterprise, Inc. (NASDAQ:AXON) by 12.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,653 shares of the biotechnology company’s stock after purchasing an additional 182 shares during the quarter. Hanlon Investment Management Inc.’s holdings in Axon Enterprise were worth $486,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. boosted its stake in Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 79 shares in the last quarter. ICA Group Wealth Management LLC bought a new position in shares of Axon Enterprise during the fourth quarter valued at $26,000. Trivant Custom Portfolio Group LLC acquired a new stake in shares of Axon Enterprise in the 1st quarter valued at $31,000. First PREMIER Bank bought a new stake in shares of Axon Enterprise in the 1st quarter worth about $33,000. Finally, Blue Bell Private Wealth Management LLC acquired a new stake in shares of Axon Enterprise during the 1st quarter worth about $41,000. 79.08% of the stock is owned by institutional investors.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total value of $167,863.50. Following the sale, the director now directly owns 7,379 shares in the company, valued at $2,752,588.37. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the transaction, the chief executive officer now directly owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the sale, the director now owns 7,379 shares in the company, valued at $2,752,588.37. The disclosure for this sale can be found here. Insiders have sold 278,650 shares of company stock worth $101,364,745 in the last ninety days. Company insiders own 6.10% of the company’s stock.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $354.62 on Friday. The firm has a fifty day moving average of $331.40 and a two-hundred day moving average of $310.85. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The stock has a market capitalization of $26.80 billion, a price-to-earnings ratio of 103.69, a PEG ratio of 9.52 and a beta of 0.94. Axon Enterprise, Inc. has a 52 week low of $189.12 and a 52 week high of $378.89.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. During the same quarter in the prior year, the company posted $0.80 earnings per share. The firm’s revenue was up 34.5% on a year-over-year basis. As a group, equities research analysts predict that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Wall Street Analysts Forecast Growth

AXON has been the topic of several research analyst reports. Craig Hallum upped their price objective on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Jefferies Financial Group assumed coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price target for the company. Bank of America started coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price objective on the stock. Barclays raised their target price on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, Robert W. Baird upped their price target on shares of Axon Enterprise from $355.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $358.08.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.